Article Text

other Versions

PDF
Immunosuppression for liver transplantation
  1. Edward Kenneth Geissler (edward.geissler{at}klinik.uni-regensburg.de)
  1. University of Regensburg, Germany
    1. Hans Juergen Schlitt (hans.schlitt{at}klinik.uni-regensburg.de)
    1. University of Regensburg, Germany

      Abstract

      In the last decades liver transplantation (LTx) has become a reliable life-saving procedure for patients with chronic end-stage liver diseases. LTx has an outstanding success rate in the first few years after allografting, especially considering that many patients are on the brink of survival at the time of transplantation. The success of LTx is owed to the pioneers who developed the surgical procedures and to researchers who discovered the medications to help prevent immunologic allograft rejection. However, several problems continue to impose serious limits on LTx today, including a shortage of donor livers, disease recurrence (e.g. hepatitis, hepatocellular cancer), preservation of long-term allograft function and anti-rejection drug side effects. While the organ shortage dilemma is not a focus of this review, we will address the latter issues as they relate to the "oldest" and "newest" approaches to immunosuppression, and discuss the prospect that recipients could potentially be made immunologically tolerant to liver transplants. Due to the critical organ shortage, new strategies to preserve transplanted liver allografts for the longest possible time are of paramount importance.

      Statistics from Altmetric.com

      • web only appendix 58/3/452

        Request permissions

        If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.